FDA approves local biotech's first rare-cancer drug

The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Abstract OBJECTIVES: To explore the feasibility of a nurse-driven telephone triage intervention to improve the symptom experience of patients with cancer receiving treatment in the ambulatory setting. SAMPLE & SETTING: 90 patients in three ambulatory centers (breast, head and neck, and sarcoma) receiving active treatment at a National Cancer Institute-designated comprehensive cancer center. METHODS & VARIABLES: Patients received 4-18 triage calls from a nurse during a period of as many as six months dependent on their diagnosis and treatment. Feasibility was defined as the completion of 70% of tr...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
AbstractMelatonin is an indole produced by the pineal gland at night under normal light or dark conditions, and its levels, which are higher in children than in adults, begin to decrease prior to the onset of puberty and continue to decline thereafter. Apart from circadian regulatory actions, melatonin has significant apoptotic, angiogenic, oncostatic, and antiproliferative effects on various cancer cells. Particularly, the ability of melatonin to inhibit skeletomuscular sarcoma, which most commonly affects children, teenagers, and young adults, is substantial. In the past few decades, the vast majority of references have ...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
SummarySoft tissue sarcomas are exceedingly rare cancers with more than 100 different histiologic subtypes and tremendous morphologic heterogeneity. Next generation sequencing (NGS) techniques have drastically improved our knowledge about these tumours. The possibility to use these techniques routinely changed the diagnostic standards in soft tissue pathology. Within the last few years pathologists were confronted with a  growing number of exceedingly rare, partly molecularly defined, tumour entities. The proposed pathologic diagnosis dictates prognosis and treatment. Therefore, specialized soft tissue pathology units...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
[Independent (Kampala)] Kampala -Agnes Emujong battles Kaposi's sarcoma, a type of cancer that usually affects people living with HIV. The disease has made her develop large protruding tumors on the nose and eye areas that have almost shrunk her face.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
hi Fujiwara Adenovirus serotype 5 (Ad5) is widely and frequently used as a virus vector in cancer gene therapy and oncolytic virotherapy. Oncolytic virotherapy is a novel antitumor treatment for inducing lytic cell death in tumor cells without affecting normal cells. Based on the Ad5 genome, we have generated three types of telomerase-specific replication-competent oncolytic adenoviruses: OBP-301 (Telomelysin), green fluorescent protein (GFP)-expressing OBP-401 (TelomeScan), and tumor suppressor p53-armed OBP-702. These viruses drive the expression of the adenoviral E1A and E1B genes under the control of the hTERT (hum...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
British Journal of Cancer, Published online: 18 February 2020; doi:10.1038/s41416-020-0748-3Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Breast Cancer;   Lung Cancer;   Gastrointestinal Cancer;   Genitourinary Cancer;   Gynecologic Cancer;   Sarcoma;   Unknown Primary Tumors;   Head and Neck Cancer;   Skin Cancer Intervention:   Drug: Atezolizumab Sponsors:   British Columbia Cancer Agency;   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionIntegrative clustering analysis revealed that the STSs could be clustered into three sub-clusters. The ceRNA network, especially the subnetwork LncRNA (KCNQ1OT1)-miRNA (has-miR-29c-3p)-mRNA (JARID2, CDK8, DNMT3A, TET1) was a promising therapeutic target for the STS sub-cluster associated with a poor prognosis.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Japan Health | Pharmaceuticals | Sarcomas